The role of voriconazole in the treatment of emerging mycoses;El papel del voriconazol en el tratamiento de las micosis emergentes

Revista Iberoamericana de Micologia

Volumn 24, Issue 3, 2007, Pages 228-232

  Pastor, F Javier ^a   Guarro, Josep ^a  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

Aspergillus terreus; Candida spp. other than Candida albicans; Emerging mycoses; Fusarium; Scedosporium; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ASPERGILLUS; ASPERGILLUS TERREUS; CANDIDA ALBICANS; CANDIDA GLABRATA; CRYPTOCOCCOSIS; DERMATOMYCOSIS; DRUG EFFICACY; EXOPHIALA; FUSARIUM; HUMAN; INVASIVE CANDIDIASIS; MYCOSIS; PAECILOMYCES LILACINUS; PENICILLIUM MARNEFFEI; PETRIELLIDIUM BOYDII; REVIEW; SCEDOSPORIUM; SCEDOSPORIUM APIOSPERMUM; SPECIES COMPARISON;

ASPERGILLUS TERREUS; CANDIDA; CANDIDA ALBICANS; FUNGI; FUSARIUM; SCEDOSPORIUM;

EID: 35348989279     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-1406(07)70048-7     Document Type: Review

References (82)

1. Anderson KL, Mitra S, Salouti R, Pham TA, Taylor HR. Fungal keratitis caused by Paecilomyces lilacinus associated with a retained intracorneal hair. Cornea 2004; 23: 516-521.
2. Baden LR, Katz JT, Fishman JA, Koziol C, DelVecchio A, Doran M, Rubin RH. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003; 76: 1632-1637.
3. Blignaut E, Molepo J, Pujol C, Soll DR, Pfaller MA. Clade-related amphotericin B resistance among South African Candida albicans isolates. Diagn Microbiol Infect Dis 2005; 53: 29-31.
4. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years experience at a cancer center and implications for management. Blood 1997; 90: 999-1008.
5. Bunya VY, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol 2007; 143: 151-153.
6. Capilla J, Guarro J. Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs. Antimicrob Agents Chemother 2004; 48: 4009-4011.
7. Capilla J, Serena C, Pastor FJ, Ortoneda M, Guarro J. Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice. Antimicrob Agents Chemother 2003; 47: 3976-3978.
8. Chakraborty A, Workman MR, Bullock PR. Scedosporium apiospermum brain abscess treated with surgery and voriconazole. J Neurosurg 2005; 103 (1 Suppl): 83-87.
9. Chandenier J, Ledu S, Machet MC, Prudhomme A, Bastides F, Bacq Y, Chandenier B, Barrabes A, Machet L, Richard-Lenoble D. Prise en charge d'un cas de paecilomycose à Paecilomyces lilacinus: apport de l'antifongigrame, guérison par chirurgie et voriconazole. J Mycol Med 2004; 14: 134-136.
10. Chaney S, Gopalan R, Berggren RE. Pulmonary Pseudallescheria boydii infection with cutaneous zygomycosis after near drowning. South Med J 2004; 97: 683-687.
11. Colombo AL, Melo ASA, Rosas RFC, Salomao R, Briones M, Hollis RJ, Messer SA, Pfaller MA. Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to emphotericin B therapy. Diagn Microbiol Infect Dis 2003; 46: 253-257.
12. Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient. Clin Infect Dis 2003; 37: 311-313.
13. Cudillo L, Girmenia C, Santilli S, Picardi A, Dentamaro T, Tendas A, de Fabritiis P. Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. Clin Infect Dis 2005; 40: 1212-1213.
14. Cuenca-Estrella M, Rodríguez D, Almirante B, Morgan J, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Salvado M, Warnock DW, Pahissa A, Rodriguez-Tudela JL on behalf of the Barcelona Candidemia Project Study Group. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005; 55: 194-199.
15. Dalton PA, Munckhof WJ, Walters DW. Scedosporium prolificans: an uncommon cause of septic arthritis. ANZ J Surg 2006; 76: 661-663.
16. Dan M, Mereuta AI, Burcoveanu C. Disseminated infections due to Scedosporium apiospermum in a patient with anaplastic large cell lymphoma. A case study. Rev Med Chir Soc Med Nat Iasi 2005; 109: 638-641.
17. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571.
18. Díaz Pedroche C, Cisneros JM, Lumbreras C, Aguado JM; Grupo Clínico Español de Estudio de Voriconazol. Tratamiento con voriconazol de las infecciones fúngicas invasoras. Evaluación de la experiencia del uso compasivo de voriconazol en España. Rev Esp Quimioter 2005; 18: 149-158.
19. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954-958.
20. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001: 150: 101-115.
21. Farina C, Gotti E, Suter F, Goglio A. Scedosporium apiospermum soft-tissue infection: a case report and review of kidney transplant literature. Transplant Proc 2006; 38: 1333-1335.
22. Garbino J, Ondrusova A, Baligvo E, Lew D, Bouchuiguir-Wafa K, Rohner P. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis 2002; 34: 701-703.
23. Gilgado F, Serena C, Cano J, Gené J, Guarro J. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother 2006; 50: 4211-4213.
24. Girmenia C, Luzi G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol 1998; 36: 1436-1438.
25. Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC. Cure of orthopedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003; 46: 233-236.
26. Graybill JR. Voriconazole for candidosis: an important addition? Lancet 2005; 366: 1413-1414.
27. Guarro J, Kantarcioglu AS, Horré R, Rodríguez-Tudela JL, Cuenca Estrella M, Berenguer J, de Hoog GS. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol 2006; 44: 295-327.
28. Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2004; 23: 1059-1061.
29. Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, Prince RA. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122: 42-47.
30. Hilmarsdottir I, Thorsteinsson SB, Asmundsson P, Bodvarsson M, Arnadottir M. Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant pacient: treatment with voriconazole. Scand J Infect Dis 2000; 32: 331-332.
31. Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses 2007; 50: 227-231.
32. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22: 111-113.
33. Husain S, Alexander B, Munoz P, Avery RK, Houston S, Pruett T, Jacobs R, Dominguez EA, Tollemar JG, Baumgarten K, Yu CM, Wagener MM, Linden P, Kusne S, Singh N. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37: 221-229.
34. Husain S, Muñoz P, Forrest G, Alexander BD, Somani J, Brennan K, Wagener MM, Singh N. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40: 89-99.
35. Kauffman CA. Fungal infections. Proc Am Thorac Soc 2006; 3: 35-40.
36. Klont RR, Eggink CA, Rijs AJ, Wesseling P, Verweij PE. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis 2005; 40: e110-112.
37. Kramer M, Kramer MR, Blau H, Bishara J, Axer-Siegel R, Weinberger D. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 2006; 113: 1184-1186.
38. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LWP, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-1442.
39. Lass-Flörl C, Griff K, Mayr A, Petzer A, Gastl G, Bonatti H, Freund M, Kropshofer G, Dierich MP, Nachbaur D. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single center experience. Br J Haemathol 2005; 131: 201-207.
40. Levêque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006; 27: 274-284.
41. Li JYZ, Yong TY, Grove DI, Coates PTH. Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient. Transpl Infect Dis 2007; doi: 10.1111/j.1399-3062.2007.00240.x.
42. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case fatality rate: systemic review of the literature. Clin Infect Dis 2001; 32: 358-366.
43. Luque P, García-Gil FA, Larraga J, Jiménez B, Tomé-Zelaya E, Serrano MT, Barrao ME. Treatment of cutaneous infection by Alternaria alternata with voriconazole in a liver transplant patient. Transplant Proc 2006; 38:2514-2515.
44. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37: 728-732.
45. Machetti M, Zotti M, Veroni L. Antigen detection in the diagnosis and management of a patient with a probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2000; 2: 140-144.
46. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44: 529-535.
47. Martin CA, Roberts S, Greenberg RN. Voriconazole treatment of disseminated Paecilomyces infection in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2002; 35: 78-81.
48. Miller NS, Dick JD, Merz WG. Phenotypic switching in Candida lusitaniae on copper sulfate indicator agar: association with amphotericin B resistance and filamentation. J Clin Microbiol 2006; 44: 1536-1539.
49. Moinfar N, Smiddy WE, Miller D, Miller D, Herschel K. Posttraumatic Aspergillus terreus endophthalmitis masquerading as dispersed lens fragments. J Cataract Refract Surg 2007; 33: 739-740.
50. Muñoz P, Marin M, Tornero P. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000; 31: 1499-1501.
51. Mursch K, Trnovec S, Ratz H, Hammer D, Horre R, Klinghammer A, de Hoog S, Behnke-Mursch J. Successful treatment of multiple Pseudallescheria boydii brain abscesses and ventriculitis/ependymitis in a 2-year-old child after a near-drowning episode. Childs Nerv Syst 2006; 22: 189-192.
52. Nesky MA, McDougal C, Peacock JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudellescheriasis. Clin Infect Dis 2000; 31: 673-677.
53. Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabaos P, Costa S, Voltarelli JC, Colombo AL, Imhof A, Pasquin R, Maiolino A, Souza CA, Anaissie E. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237-1242.
54. Nulens E, Eggink C, Rijs AJ, Wesseling P, Verweij E. Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol 2003; 41: 2261-2264.
55. Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infec Dis 2003; 22: 651-655.
56. O'Sullivan MVN, Withby M, Hirst LW, Apel AJG, Ellis D. Outcome of Paecilomyces species ophthalmic infections treated with systemic voriconazole. Washington, 43rd ICAAC, 2003. Abstract No: M-972.
57. Ozbek Z, Kang S, Sivalingam J, Rapuano C, Cohen E, Hammersmith K. Voriconazole in the management of Alternaria keratitis. Cornea 2006; 25: 242-244.
58. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006; 44: 1740-1743.
59. Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect 2006; 12: 948-960.
60. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366: 1013-1025.
61. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nübling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131.
62. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
63. Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, Tiraboschi N, Nagy E, Gibbs DL, and the Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeasts species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43: 5848-5859.
64. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, Diekema DJ. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48: 201-205.
65. Porte L, Khatibi S, Hajj LE, Cassaing S, Berry A, Massip P, Linas MD, Magnaval JF, Sans N, Marchou B. Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole. Trans R Soc Trop Med Hyg 2006; 100: 891-894.
66. Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 2000; 84: 932-933.
67. Rodriguez CA, Luján-Zilbermann J, Woodard P, Andreansky M, Adderson EE. Successful treatment of disseminated fusariosis. Bone Marrow Transplant 2003; 31: 411-412.
68. Sabbatani S, Manfredi R, Pavoni M, Consales A, Chiodo F. Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIV-negative patient, after fluconazole failure. Mycopathologia 2004; 158: 165-171.
69. Sagnelli C, Fumagalli L, Prigitano A, Baccari P, Magnani P, Lazzarin A. Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy. J Antimicrob Chemother 2006: 57: 796-798.
70. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997; 97: 663-665.
71. Serena C, Pastor FJ, Mariné M, Rodríguez MM, Guarro J. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother 2007; 60: 162-165.
72. Shankar S, Biswas J, Gopal L, Bagyalakshmi R, Therese L, Borse NJ. Anterior chamber exudative mass due to Scedosporium apiospermum in an immunocompetent individual. Indian J Ophthalmol 2007; 55: 226-227.
73. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43: 1060-1068.
74. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42: 244-251.
75. Stanzani M, Vianelli N, Bandini G, Paolini S, Arpinati M, Bonifazi F, Giannini B, Agostinelli C, Baccarani M, Ricci P. Successful treatment of disseminated fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B. J Infect 2006; 53: e243-e246.
76. Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-198.
77. Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol 2003; 41: 3981-3985.
78. Tattevin P, Bruneel F, Lellouche F, de Broucker T, Chevret S, Wolff M, regnier B. Successful treatment of brain aspergillosis with voriconazole. Clin Microbiol Infect 2004; 10: 928-931.
79. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lutsar I. Voriconazole (VORI) for the treatment of S. apiospermum and S. prolificans infection. New Orleans, 38th Annual Meeting of the IDSA, 2000. Abstract No: 305.
80. Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol 1999; 37: 1186-1189.
81. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-248.
82. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.